Toleranzia AB — Investor Relations & Filings

Toleranzia AB was a biotechnology company focused on developing treatments for autoimmune orphan diseases. The company's technology platform was designed to induce immune tolerance, addressing the underlying cause of the disease. Its primary drug candidate, TOL2, was in development for the treatment of the rare neuromuscular disorder myasthenia gravis. In August 2025, Toleranzia AB was dissolved following a merger with Flerie AB. All of Toleranzia's assets, liabilities, and operations were transferred to Flerie and are now continued within a new subsidiary, Bonsai Biotherapeutics AB.